Peripheral SpA: Dr. Antoni Chan and Dr. Nelly Ziade Dr. Chan ( @synovialjoints) interviews Dr. Ziade about abstract #1787 presented at the #ACR21 annual meeting. https://t.co/Sdd1HHKRib https://t.co/ynRocjviVu

• https://bit.ly/3bSr3J2

ePROs for SpA patients showed a trend in reduction of disease activity, improved clinic workload, individualized treatment with good patient/physician user satisfaction Abs#1788 #ACR21 @RheumNow https://t.co/04kUikdIZu https://t.co/uO9junUqKi

• https://bit.ly/3mUUX5M

Avoid IFX drug holidays! In this study 400+ pts Dvlpmt of ADAs associated w/ ▶️RA vs. SPA OR 2.1 ▶️Smoking OR 1.8 ▶️Drug holidays > 11 weeks OR 4.1 ▶️High DA OR 1.5 while ◀️Concomitant IS drug OR 0.4 ◀️ IFX dose increments OR 0.4, were protective #ACR21 @RheumNow #Abst1525 https://t.co/cxx7aWX5wh

Safety profile of #upadacitinib in #RA, #PsA, #AnkylosingSpondylitis 👉🏼AE rates similar across UPA, ADA & MTX in RA, and UPA & ADA in PsA 👉🏼No new safety risks with long-term use 👉🏼#Herpeszoster & incr CPK more common w/ UPA vs ADA/MTX Abs#1691 #ACR21 @RheumNow https://t.co/tKYi65kB5r

Watch my video summary of abstracts #0380 and #0381 presented at the #ACR21 on #SickLeave and #WorkDisability in #axSpA by @ElenaNikiUK and colleagues. @RheumNow https://t.co/HWEyPoPJi0

• Dr. John Cush on Twitter: "Sick Leave and Work Disability in Patients with…

For Dr @LianneGensler managing axSpA requires a sundae🍨approach! How cool is that?!😎 This means that we need to take a holistic approach on the management of axSpA - both non/pharmacologic & there's no one magic pill to treat the disease. @RheumNow #ACR21 #RheumTwitter https://t.co/o0OjcEn16b

Sick Leave and Work Disability in Patients with AxSpA: Dr. Mrinalini Dey ( @DrMiniDey) discusses abstracts #0380 and #0381 presented at the #ACR21 annual meeting. https://t.co/Wm4qpxerYJ https://t.co/6CwPrZjqJT

• https://bit.ly/3CVHznj